It really matters who is in the room you’re in. Two years ago Lara and I pitched at the inaugural Merck Healthcare / M Ventures W Accelerate Innovation programme run by W Group The event was fantastic. The seniority of the people in that room were impressive, and the conversations that started there became the …

Original article here Calla Lily joins $50M program targeting antibiotic resistance A new intravaginal drug delivery platform has been selected to investigate whether localized UTI treatment can reduce the collateral effects of systemic antibiotics. Written by Bree Foster, PhD Aug 11, 2026 New approaches aim to target infections while sparing the gut microbiome. credit: istock.com/Scharvik …

We do not believe many other London based start-ups have their own labs to be able to manufacture products, but here at Calla Lily Clinical Care, we have done exactly that. All of our Callavid® design validation and clinical trial products started their production here in London. Now that our clinical trial is underway, our …

What a way to close out Day 2 of ESHRE 2026! 🌅 We were delighted to co-host an European Society of Human Reproduction and Embryology (ESHRE) Sundowner with our brilliant partners Hertility and Impli… held on the rooftop of the Lillet Bar overlooking the Thames and the iconic London skyline. 🚠 The energy was electric …

It’s been an intense but very productive 42nd European Society of Human Reproduction and Embryology (ESHRE) Congress – the world’s largest gathering of professionals in reproductive medicine and embryology, held at Excel London. 🌸 So many great conversations, catch-ups and new connections forged: all united by a shared mission to improve fertility outcomes in the …

FREEDOM trial reaches 100% patient consent. Calla Lily Clinical Care is pleased to share an important milestone in our NIHR funded FREEDOM clinical trial. In less than three months since recruitment began, FREEDOM has passed its safety stopping rule, and all target patient participants are now consented. More than half of total participants have also …

With our FREEDOM clinical trial making exciting progress– now 60% recruited — we are delighted to start receiving national media coverage for this important step towards a more patient-centric option for women suffering from threatened miscarriage. A big thank you to the Daily Mail for featuring Callavid® and our University Hospitals Coventry and Warwickshire (UHCW) …

Our colleagues Ewa Radziwon and Shaun Knights had a very productive few days at INDEX Nonwovens INDEX™26 in #Geneva, hosted by EDANA, the voice of nonwovens 🇨🇭 As the world’s leading nonwovens exhibition, it was important for Calla Lily Clinical Care to attend again: reconnecting with existing suppliers, meeting potential new partners, and exploring exciting …

It was recently World Clinical Trials Day, and our co-founder Lara took part in a special event hosted by SökerData and Covington & Burling LLP: 🔬 “Innovation in Action: Successful Women’s Clinical Trial Case Studies” 🧪 Lara shared the context, design and exciting early progress of our ongoing FREEDOM clinical trial evaluating Callavid® for threatened …

Original article here Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage by John Pinching | 7th May 2026 | News Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the company’s Callavid …